Start Date
December 1, 2021
Primary Completion Date
July 1, 2022
Study Completion Date
December 1, 2022
QVM149
QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
High Dose Dual Therapy (ICS/LABA)
High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
Robarts Research Insitute; The University of Western Ontario; London Health Sciences Centre, London
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Dr. Grace Parraga
OTHER